---
title: "Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300204.SZ.md"
symbol: "300204.SZ"
name: "Staidson (Beijing) Biopharmaceuticals Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T03:37:33.841Z"
locales:
  - [en](https://longbridge.com/en/quote/300204.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300204.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300204.SZ.md)
---

# Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204.SZ)

## Company Overview

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release tablets, Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.staidson.com](https://www.staidson.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 68 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -30.42% |  |
| Net Profit YoY | 41.52% |  |
| P/B Ratio | 15.59 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12610697269.16 |  |
| Revenue | 203720726.41 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -9.51% | D |
| Profit Margin | -41.12% | E |
| Gross Margin | 78.19% | A |
| Revenue YoY | -30.42% | E |
| Net Profit YoY | 41.52% | B |
| Total Assets YoY | 10.22% | B |
| Net Assets YoY | -15.68% | E |
| Cash Flow Margin | 155.39% | B |
| OCF YoY | -30.42% | E |
| Turnover | 0.17 | D |
| Gearing Ratio | 37.94% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Staidson (Beijing) Biopharmaceuticals Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-30.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "41.52%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "15.59",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12610697269.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "203720726.41",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-9.51%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-41.12%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "78.19%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-30.42%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "41.52%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.22%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-15.68%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "155.39%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-30.42%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "37.94%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -151.95 | 77/81 | - | - | - |
| PB | 15.73 | 73/81 | 20.26 | 16.31 | 14.84 |
| PS (TTM) | 62.49 | 80/81 | 70.77 | 60.22 | 52.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-14T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 44.64 |
| Highest Target | 55.24 |
| Lowest Target | 55.24 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300204.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300204.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300204.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300204.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**